|
1
|
Galle PR, Forner A, Llovet JM, Mazzaferro
V, Piscaglia F, Raoul JL, Schirmacher P and Vilgrain V; European
Association for the Study of the Liver, : EASL Clinical Practice
Guidelines: Management of hepatocellular carcinoma. J Hepatol.
69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu XJ, Shi Y, Chen JL and Ma S:
Krüppel-like factors in hepatocellular carcinoma. Tumour Biol.
36:533–541. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu WB, Rao A, Vu V, Xu L, Rao JY and Wu
JX: Management of centrally located hepatocellular carcinoma:
Update 2016. World J Hepatol. 9:627–634. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Portolani N, Coniglio A, Ghidoni S,
Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late
recurrence after liver resection for hepatocellular carcinoma:
Prognostic and therapeutic implications. Ann Surg. 243:229–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu J and Gao DZ: Distinction immune genes
of hepatitis-induced heptatocellular carcinoma. Bioinformatics.
28:3191–3194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marquardt JU, Galle PR and Teufel A:
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC):
An emerging field for advanced technologies. J Hepatol. 56:267–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bolanos-Garcia VM and Blundell TL: BUB1
and BUBR1: Multifaceted kinases of the cell cycle. Trends Biochem
Sci. 36:141–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson VL, Scott MI, Holt SV, Hussein D
and Taylor SS: Bub1 is required for kinetochore localization of
BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J Cell
Sci. 117:1577–1589. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu H and Tang Z: Bub1 multitasking in
mitosis. Cell Cycle. 4:262–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ricke RM, Jeganathan KB and van Deursen
JM: Bub1 overexpression induces aneuploidy and tumor formation
through Aurora B kinase hyperactivation. J Cell Biol.
193:1049–1064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin
ZY, Wu YD, Liang YX, Han ZD, Liu JC, et al: Overexpression of BUB1B
contributes to progression of prostate cancer and predicts poor
outcome in patients with prostate cancer. Onco Targets Ther.
9:2211–2220. 2016.PubMed/NCBI
|
|
13
|
Piao J, Zhu L, Sun J, Li N, Dong B, Yang Y
and Chen L: High expression of CDK1 and BUB1 predicts poor
prognosis of pancreatic ductal adenocarcinoma. Gene. 701:15–22.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han JY, Han YK, Park GY, Kim SD and Lee
CG: Bub1 is required for maintaining cancer stem cells in breast
cancer cell lines. Sci Rep. 5:159932015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stahl D, Braun M, Gentles AJ, Lingohr P,
Walter A, Kristiansen G and Gütgemann I: Low BUB1 expression is an
adverse prognostic marker in gastric adenocarcinoma. Oncotarget.
8:76329–76339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen QF, Xia JG, Li W, Shen LJ, Huang T
and Wu P: Examining the key genes and pathways in hepatocellular
carcinoma development from hepatitis B virus-positive cirrhosis.
Mol Med Rep. 18:4940–4950. 2018.PubMed/NCBI
|
|
17
|
Zhang L, Huang Y, Ling J, Zhuo W, Yu Z,
Shao M, Luo Y and Zhu Y: Screening and function analysis of hub
genes and pathways in hepatocellular carcinoma via bioinformatics
approaches. Cancer Biomark. 22:511–521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen DY, Lin P, Pang YY, Chen G, He Y, Dang
YW and Yang H: Expression of the long intergenic non-protein coding
RNA 665 (LINC00665) gene and the cell cycle in hepatocellular
carcinoma using the Cancer Genome Atlas, the Gene Expression
Omnibus, and Quantitative Real-Time Polymerase Chain Reaction. Med
Sci Monit. 24:2786–2808. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Liu DP, Chen PP, Koeffler HP, Tong
XJ and Xie D: Involvement of IFN regulatory factor (IRF)-1 and
IRF-2 in the formation and progression of human esophageal cancers.
Cancer Res. 67:2535–2543. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williams GL, Roberts TM and Gjoerup OV:
Bub1: Escapades in a cellular world. Cell Cycle. 6:1699–1704. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L, Xu DB, Zhao XL and Hao TY:
Combination analysis of Bub1 and Mad2 expression in endometrial
cancer: Act as a prognostic factor in endometrial cancer. Arch
Gynecol Obstet. 288:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mukherjee A, Joseph C, Craze M,
Chrysanthou E and Ellis IO: The role of BUB and CDC proteins in
low-grade breast cancers. Lancet. 385 (Suppl 1):S722015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takagi K, Miki Y, Shibahara Y, Nakamura Y,
Ebata A, Watanabe M, Ishida T, Sasano H and Suzuki T: BUB1
immunolocalization in breast carcinoma: Its nuclear localization as
a potent prognostic factor of the patients. Horm Cancer. 4:92–102.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A,
Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B,
Pandiella A and Amir E: In silico analyses identify gene-sets,
associated with clinical outcome in ovarian cancer: Role of mitotic
kinases. Oncotarget. 7:22865–22872. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dituri F, Mancarella S, Cigliano A, Chieti
A and Giannelli G: TGF-β as multifaceted orchestrator in HCC
progression: signaling, EMT, immune microenvironment, and novel
therapeutic perspectives. Semin Liver Dis. 39:53–69. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wrana JL, Attisano L, Wieser R, Ventura F
and Massagué J: Mechanism of activation of the TGF-beta receptor.
Nature. 370:341–347. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
